Literature DB >> 22016837

The mass-action law based algorithm for cost-effective approach for cancer drug discovery and development.

Ting-Chao Chou1.   

Abstract

The mass-action law based system analysis via mathematical induction and deduction lead to the generalized theory and algorithm that allows computerized simulation of dose-effect dynamics with small size experiments using a small number of data points in vitro, in animals, and in humans. The median-effect equation of the mass-action law deduced from over 300 mechanism specific-equations has been shown to be the unified theory that serves as the common-link for complicated biomedical systems. After using the median-effect principle as the common denominator, its applications are mechanism-independent, drug unit-independent, and dynamic order-independent; and can be used generally for single drug analysis or for multiple drug combinations in constant-ratio or non-constant ratios. Since the "median" is the common link and universal reference point in biological systems, these general enabling lead to computerized quantitative bio-informatics for econo-green bio-research in broad disciplines. Specific applications of the theory, especially relevant to drug discovery, drug combination, and clinical trials, have been cited or illustrated in terms of algorithms, experimental design and computerized simulation for data analysis. Lessons learned from cancer research during the past fifty years provide a valuable opportunity to reflect, and to improve the conventional divergent approach and to introduce a new convergent avenue, based on the mass-action law principle, for the efficient cancer drug discovery and the low-cost drug development.

Entities:  

Keywords:  Drug discovery; ardeemin and immunosuppression; combination index; computer simulation; conservation of animals; diagnostic plot; dose-reduction index; drug combination; drug development; econo-green revolution for bio-research; experimental design; iso-oxazole-fludelone and epothilones; median-effect equation and plot of the mass-action law; pharmacodynamics; polygonogram; small size experiment; synergy definition; therapeutic cure of xenograft tumor; unified theory for dose-effect pharmacodynamics

Year:  2011        PMID: 22016837      PMCID: PMC3196289     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  23 in total

1.  The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice.

Authors:  T C Chou; O A O'Connor; W P Tong; Y Guan; Z G Zhang; S J Stachel; C Lee; S J Danishefsky
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

2.  Interaction index and different methods for determining drug interaction in combination therapy.

Authors:  J J Lee; M Kong; G D Ayers; R Lotan
Journal:  J Biopharm Stat       Date:  2007       Impact factor: 1.051

3.  Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel.

Authors:  T C Chou; X G Zhang; C R Harris; S D Kuduk; A Balog; K A Savin; J R Bertino; S J Danishefsky
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

4.  There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture.

Authors:  D D Von Hoff
Journal:  Clin Cancer Res       Date:  1998-05       Impact factor: 12.531

Review 5.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

6.  Relationships between inhibition constants and fractional inhibition in enzyme-catalyzed reactions with different numbers of reactants, different reaction mechanisms, and different types and mechanisms of inhibition.

Authors:  T Chou
Journal:  Mol Pharmacol       Date:  1974-03       Impact factor: 4.436

7.  Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Eur J Biochem       Date:  1981-03-16

8.  Therapeutic cure against human tumor xenografts in nude mice by a microtubule stabilization agent, fludelone, via parenteral or oral route.

Authors:  Ting-Chao Chou; Huajin Dong; Xiuguo Zhang; William P Tong; Samuel J Danishefsky
Journal:  Cancer Res       Date:  2005-10-15       Impact factor: 12.701

9.  A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems.

Authors:  T C Chou; P Talalay
Journal:  J Biol Chem       Date:  1977-09-25       Impact factor: 5.486

10.  Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design.

Authors:  T C Chou; R J Motzer; Y Tong; G J Bosl
Journal:  J Natl Cancer Inst       Date:  1994-10-19       Impact factor: 13.506

View more
  21 in total

1.  Chitosan Hydrogels for Synergistic Delivery of Chemotherapeutics to Triple Negative Breast Cancer Cells and Spheroids.

Authors:  John D Schneible; Ashlyn T Young; M A Daniele; S Menegatti
Journal:  Pharm Res       Date:  2020-07-13       Impact factor: 4.200

2.  Drug repurposing identifies a synergistic combination therapy with imatinib mesylate for gastrointestinal stromal tumor.

Authors:  Ziyan Y Pessetto; Yan Ma; Jeff J Hirst; Margaret von Mehren; Scott J Weir; Andrew K Godwin
Journal:  Mol Cancer Ther       Date:  2014-08-13       Impact factor: 6.261

3.  Synergistic inhibitory effect of wogonin and low-dose paclitaxel on gastric cancer cells and tumor xenografts.

Authors:  Tingting Wang; Jing Gao; Jingwei Yu; Lin Shen
Journal:  Chin J Cancer Res       Date:  2013-10       Impact factor: 5.087

4.  Curcumin, thymoquinone, and 3, 3'-diindolylmethane combinations attenuate lung and liver cancers progression.

Authors:  Amna A Saddiq; Ali H El-Far; Shymaa Abdullah Mohamed Abdullah; Kavitha Godugu; Omar A Almaghrabi; Shaker A Mousa
Journal:  Front Pharmacol       Date:  2022-06-29       Impact factor: 5.988

5.  Regorafenib Reverses Temozolomide-Induced CXCL12/CXCR4 Signaling and Triggers Apoptosis Mechanism in Glioblastoma.

Authors:  I-Tsang Chiang; Yu-Chang Liu; Hua-Shan Liu; Ahmed Atef Ahmed Ali; Szu-Yi Chou; Tsung-I Hsu; Fei-Ting Hsu
Journal:  Neurotherapeutics       Date:  2022-03-10       Impact factor: 6.088

6.  Modified gaphene oxide (GO) particles in peptide hydrogels: a hybrid system enabling scheduled delivery of synergistic combinations of chemotherapeutics.

Authors:  John D Schneible; Kaihang Shi; Ashlyn T Young; Srivatsan Ramesh; Nanfei He; Clay E Dowdey; Jean Marie Dubnansky; Radina L Lilova; Wei Gao; Erik Santiso; Michael Daniele; Stefano Menegatti
Journal:  J Mater Chem B       Date:  2020-05-06       Impact factor: 6.331

7.  Synergistic combination of microtubule targeting anticancer fludelone with cytoprotective panaxytriol derived from panax ginseng against MX-1 cells in vitro: experimental design and data analysis using the combination index method.

Authors:  Ning Zhang; Jia-Ning Fu; Ting-Chao Chou
Journal:  Am J Cancer Res       Date:  2015-12-15       Impact factor: 6.166

8.  In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma.

Authors:  Ziyan Y Pessetto; Bin Chen; Hani Alturkmani; Stephen Hyter; Colleen A Flynn; Michael Baltezor; Yan Ma; Howard G Rosenthal; Kathleen A Neville; Scott J Weir; Atul J Butte; Andrew K Godwin
Journal:  Oncotarget       Date:  2017-01-17

9.  A novel preventive strategy against HIV-1 infection: combinatorial use of inhibitors targeting the nucleocapsid and fusion proteins.

Authors:  Yu Yang; Jingyu Zhu; Matthew Hassink; Lisa M Miller Jenkins; Yanmin Wan; Daniel H Appella; Jianqing Xu; Ettore Appella; Xiaoyan Zhang
Journal:  Emerg Microbes Infect       Date:  2017-06-07       Impact factor: 7.163

10.  Optimizing combinations of flavonoids deriving from astragali radix in activating the regulatory element of erythropoietin by a feedback system control scheme.

Authors:  Hui Yu; Wendy L Zhang; Xianting Ding; Ken Y Z Zheng; Chih-Ming Ho; Karl W K Tsim; Yi-Kuen Lee
Journal:  Evid Based Complement Alternat Med       Date:  2013-04-30       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.